The frequency of occurrence of anti-cardiac receptor autoantibodies and their correlation with clinical manifestation in patients with hypertrophic cardiomyopathy
S. Peukert et al., The frequency of occurrence of anti-cardiac receptor autoantibodies and their correlation with clinical manifestation in patients with hypertrophic cardiomyopathy, AUTOIMMUN, 29(4), 1999, pp. 291-297
The purpose of this study was to investigate the frequency of occurrence of
autoantibodies against G-protein coupled cardiovascular receptors and thei
r relation to the clinical manifestation of hypertrophic cardiomyopathy (HC
M). Autoantibodies against beta(1)-receptors, Muscarin-2-receptors, Angiote
nsin-II-receptor subtype I and al-receptors were determined with ELISA in 5
2 patients with HCM (37 male, 15 female, mean age 55 +/- 15 years) and 40 h
ealthly, age and sex matched controls. The clinical characterization of the
HCM-patients included EGG, 24-h Holter, and echocardiography.
The results shelved that there is no significant difference in the frequenc
y of a single autoantibody between HCM-patients and controls. However, if t
he number of patients who have autoantibodies against beta(1)-receptors and
/or Muscarin-2-receptors were counted together, there are significantly mor
e autoantibodies in HCM compared to controls (11 vs. 2, p = 0.035). Analysi
s of clinical data from this pooled group of patients showed that in patien
ts with autoantibodies, heart rate variability HRV), ultra low frequency (U
LF) and very low frequency (VLF) were decreased (HRV) by 20%, ULF by 50%, a
nd ULF by 46%, p < 0.008) whereas the QT(c)-interval was increased by 8% (p
< 0.02 each). The ratio of septal to posterior wall thickness was increase
d by 23% (p = 0.05), and the preejection period was prolonged by 46% in pat
ients with autoantibodies (p < 0.001).
These results suggest that the existence of these autoantibodies could be a
ssociated with an advanced stage or a severe manifestation of HCM.